mail
Our partnership aims to create a multi-modal deep-learning tool (TelDem tool) to analyze neuroimaging data, cognitive scores, and fluid biomarkers to classify and predict the progression of dementia syndromes. This tool can assist in diagnosing and determining the best treatment options for dementia patients. Its versatility enables it to be used in various healthcare settings, from specialized centers in urban areas to rural clinics that lack specialists. Furthermore, the TelDem tool holds the potential to facilitate the identification of the most suitable patient cohort for clinical trials evaluating novel treatments for dementia.
A major challenge faced by clinical researchers in Prof. Schroeter's group has been extracting valuable insights from fragmented, sparse, and poorly harmonized medical data from multiple organizations. The partnership with AICURA's innovative data x AI platform streamlines the process of accessing and curating clinical data, resulting in time savings of up to 70% across all data engineering workflows. Moreover, the AICURA platform equips clinical researchers with advanced machine-learning techniques that effectively handle complex multimodal, sparse, and incomplete medical datasets, yielding highly accurate prediction models.
Inspired by transformer-based model architectures that fueled the latest advancements of large language models, the TelDem tool will have the unique capability of integrating various data modalities like images, clinical scores or laboratory measurements while being able to handle missing or incomplete data without compromising diagnostic precision. This is particularly relevant in healthcare settings where the clinical decision process is based on multimodal information of patients, but the available data sets contain many missing data points.
AICURA is excited about the partnership's potential to enhance the team's expertise in neurodegenerative diseases (NDD) and optimize dementia syndrome diagnosis and treatment using its data x AI platform. The TelDem tool will be particularly impactful for remote clinics with scarce specialized resources and healthcare settings lacking full medical data. Through this partnership and the development of the TelDem tool, AICURA continues to pursue its mission to directly enhance patient care.
For more information about this collaboration project and how AICURA data x AI platform is accelerating clinical research please contact us directly or schedule a demo at info@aicura-medical.com or schedule a demo
AICURA is a leading data and AI company with a focus on healthcare and life sciences. With a mission to enhance patient outcomes, AICURA has built a secure and collaborative data and AI ecosystem. The AICURA platform simplifies the process of data aggregation, exploration, and curation, and leverages AI for automated data analysis and predictive models. AICURA connects various stakeholders, including biotech firms, healthcare providers, medtech companies, clinical researchers, and Contract Research Organizations (CROs), establishing a comprehensive network for data, technology, and knowledge transfer across the healthcare industry. This ecosystem accelerates scalable data-driven research, expedites and de-risks drug development, improves patient care, and fosters AI-based product innovation, paving the way for better treatment options for patients.
Prof. Schroeter and his group are pioneers in the field of Cognitive Neuropsychiatry, with a specific focus on neurodegenerative diseases such as dementia. Leveraging advanced imaging techniques including MRI, FDG-PET and Tau-PET alongside behavioral psychology, their interdisciplinary approach aims to establish links between cognitive deficits and specific brain structures and predict differential diagnosis, symptoms and treatment efficacy. Their efforts are aimed to advancing the understanding and treatment of neuropsychiatric disorders, offering the potential for groundbreaking therapeutic strategies.
